• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

银纳米复合材料对利福平耐药结核分枝杆菌菌株的疗效和安全性。

EFFICACY AND SAFETY OF SILVER NANOCOMPOSITES ON RIFAMPICIN-RESISTANT M. TUBERCULOSIS STRAINS.

机构信息

1Ivane Javakhishvili Tbilisi State University, Georgia.

2National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.

出版信息

Georgian Med News. 2024 Jun(351):102-108.

PMID:39230231
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11700506/
Abstract

BACKGROUND

Control of rifampicin-resistant tuberculosis (RR-MTB) requires novel technologies for restoring the anti-TB efficacy of priority drugs. We sought to evaluate the ability of nanotechnology application in the recovery of the anti-tuberculosis efficacy of rifampicin.

METHODS

Nanocomposite- standard dose of rifampicin and 20 nm silver nanoparticles (AgNPs) suspension solution of 6 different concentrations: 0.25%; 0.5%; 1%; 2.5%; 5%; and 10%, were supplemented to 70 rifampicin-resistant mycobacterium tuberculosis (RR-MTB) isolates. The control arm consisted of 35 RR-MTB isolates and AgNPs suspension with identical concentrations. The inhibitory effect of nanocomposites was evaluated by MTB growth rate using the BACTECTM MGIT 960TM. The safety assessment of single-use AgNPs was conducted in experimental animals.

RESULTS

The suppression process of AgNPs on RR-MTB isolates started with 2,5% nanocomposite solution application and full suppression was achieved in 5% and 10% nanocomposite solutions. A standard dose of rifampicin and a 2.5% solution of AgNPs increased the minimal inhibitory effect on RR-MTB by 10% (total 80%) vs the isolated use of a 2.5% solution of AgNPs (70%). An experiment on animals revealed the complete safety of a single injection of ultra-high doses of AgNPs.

CONCLUSION

The study showed the potentiating effect of AgNPs in overcoming the resistance of MTB to rifampicin providing a scientific basis for further research.

摘要

背景

控制利福平耐药结核病(RR-MTB)需要新的技术来恢复优先药物的抗结核疗效。我们试图评估纳米技术在恢复利福平抗结核疗效方面的应用能力。

方法

将标准剂量的利福平与浓度为 0.25%、0.5%、1%、2.5%、5%和 10%的 20nm 银纳米粒子(AgNPs)混悬液共 6 种不同浓度的纳米复合材料添加到 70 株利福平耐药结核分枝杆菌(RR-MTB)分离株中。对照组由 35 株 RR-MTB 分离株和具有相同浓度的 AgNPs 混悬液组成。使用 BACTECTM MGIT 960TM 评估纳米复合材料对 MTB 生长率的抑制作用。在实验动物中进行单次使用 AgNPs 的安全性评估。

结果

AgNPs 对 RR-MTB 分离株的抑制作用始于 2.5%纳米复合材料溶液的应用,而在 5%和 10%纳米复合材料溶液中完全抑制。标准剂量的利福平和 2.5%的 AgNPs 溶液将 RR-MTB 的最小抑菌作用提高了 10%(总 80%),而单独使用 2.5%的 AgNPs 溶液提高了 70%。动物实验表明,单次注射超高剂量的 AgNPs 是完全安全的。

结论

该研究表明 AgNPs 具有增强作用,可以克服 MTB 对利福平的耐药性,为进一步研究提供了科学依据。

相似文献

1
EFFICACY AND SAFETY OF SILVER NANOCOMPOSITES ON RIFAMPICIN-RESISTANT M. TUBERCULOSIS STRAINS.银纳米复合材料对利福平耐药结核分枝杆菌菌株的疗效和安全性。
Georgian Med News. 2024 Jun(351):102-108.
2
USAGE OF SILVER NANOPARTICLES TO RESTORE MOXIFLOXACIN EFFICACY FOR FLUOROQUINOLONE-RESISTANT M. TUBERCULOSIS CULTURES.使用纳米银颗粒恢复莫西沙星对氟喹诺酮耐药结核分枝杆菌培养物的疗效。
Georgian Med News. 2024 Sep(354):6-12.
3
[Study on the resistance of rifampicin-resistant Mycobacterium tuberculosis to anti-tuberculosis drugs in group A].A组耐利福平结核分枝杆菌对抗结核药物的耐药性研究
Zhonghua Jie He He Hu Xi Za Zhi. 2023 Nov 12;46(11):1110-1117. doi: 10.3760/cma.j.cn112147-20230804-00046.
4
Reevaluating Rifampicin Breakpoint Concentrations for Mycobacterium tuberculosis Isolates with Disputed Mutations and Discordant Susceptibility Phenotypes.重新评估具有争议性突变和不一致药敏表型的结核分枝杆菌分离株的利福平断点浓度。
Microbiol Spectr. 2022 Feb 23;10(1):e0208721. doi: 10.1128/spectrum.02087-21. Epub 2022 Feb 2.
5
Frequency of MTB and rifampicin resistance MTB using Xpert-MTB/RIF assay among adult presumptive tuberculosis patients in Tigray, Northern Ethiopia: A cross sectional study.在埃塞俄比亚提格雷北部,使用 Xpert-MTB/RIF 检测成人疑似肺结核患者中 MTB 和利福平耐药 MTB 的频率:一项横断面研究。
PLoS One. 2020 Nov 4;15(11):e0240361. doi: 10.1371/journal.pone.0240361. eCollection 2020.
6
Preliminary evaluation of anti-tuberculosis potential of siderophores against drug-resistant Mycobacterium tuberculosis by mycobacteria growth indicator tube-drug sensitivity test.通过分枝杆菌生长指示管-药敏试验对铁载体抗耐药结核分枝杆菌的抗结核潜力进行初步评估。
BMC Complement Altern Med. 2017 Mar 21;17(1):161. doi: 10.1186/s12906-017-1665-8.
7
Evaluation of extracts from used Xpert MTB/RIF cartridges for detection of resistance to second-line anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis in Ethiopia.评估埃塞俄比亚耐多药结核病患者使用过的Xpert MTB/RIF检测卡提取物对二线抗结核药物的耐药性检测情况。
BMC Microbiol. 2025 Jan 17;25(1):26. doi: 10.1186/s12866-025-03746-6.
8
Impact of line probe assay-based molecular testing on individualized treatment in patients with rifampicin-resistant tuberculosis: data from the prospective INNOVA4TB cohort study in Ukraine.基于线探针检测的分子检测对利福平耐药结核病患者个体化治疗的影响:来自乌克兰前瞻性 INNOVA4TB 队列研究的数据。
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241249841. doi: 10.1177/17534666241249841.
9
Analytical and clinical performance characteristics of the Abbott RealTime MTB RIF/INH Resistance, an assay for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis in pulmonary specimens.雅培实时MTB利福平/异烟肼耐药性检测法的分析及临床性能特征,该检测法用于检测肺部标本中耐利福平和异烟肼的结核分枝杆菌。
Tuberculosis (Edinb). 2016 Dec;101:137-143. doi: 10.1016/j.tube.2016.09.006. Epub 2016 Sep 22.
10
Detection of Rifampicin Resistance rpoB Gene Using GeneXpert MTB/RIF Assay in Pulmonary Tuberculosis Cases at Debre Tabor Comprehensive Specialized Hospital, Northwest Ethiopia.GeneXpert MTB/RIF 检测在埃塞俄比亚西北部德布雷塔博尔综合专科医院肺结核病例中的利福平耐药 rpoB 基因。
J Clin Lab Anal. 2024 Nov;38(22):e25111. doi: 10.1002/jcla.25111. Epub 2024 Oct 10.

本文引用的文献

1
Linezolid resistance in multidrug-resistant mycobacterium tuberculosis: A systematic review and meta-analysis.耐多药结核分枝杆菌对利奈唑胺的耐药性:一项系统评价和荟萃分析。
Front Pharmacol. 2022 Aug 30;13:955050. doi: 10.3389/fphar.2022.955050. eCollection 2022.
2
Bedaquiline and clofazimine: successes and challenges.贝达喹啉与氯法齐明:成效与挑战
Lancet Microbe. 2020 Aug;1(4):e139-e140. doi: 10.1016/S2666-5247(20)30097-5. Epub 2020 Aug 6.
3
Drug resistant TB - latest developments in epidemiology, diagnostics and management.
耐药结核病——流行病学、诊断与管理的最新进展
Int J Infect Dis. 2022 Nov;124 Suppl 1:S20-S25. doi: 10.1016/j.ijid.2022.03.026. Epub 2022 Mar 25.
4
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study.评估利福平耐药结核病患者对贝达喹啉耐药的流行病学、遗传特征和临床结局:一项横断面和纵向研究。
Lancet Infect Dis. 2022 Apr;22(4):496-506. doi: 10.1016/S1473-3099(21)00470-9. Epub 2021 Nov 12.
5
Nanoparticles as therapeutic options for treating multidrug-resistant bacteria: research progress, challenges, and prospects.纳米颗粒作为治疗多重耐药菌的治疗选择:研究进展、挑战和前景。
World J Microbiol Biotechnol. 2021 May 28;37(6):108. doi: 10.1007/s11274-021-03070-x.
6
Silver Nanoparticles for the Therapy of Tuberculosis.银纳米颗粒治疗结核病。
Int J Nanomedicine. 2020 Mar 31;15:2231-2258. doi: 10.2147/IJN.S241183. eCollection 2020.
7
Rifampicin conjugated silver nanoparticles: a new arena for development of antibiofilm potential against methicillin resistant and .利福平偶联银纳米粒子:开发抗耐甲氧西林金黄色葡萄球菌和 生物膜潜力的新领域。
Int J Nanomedicine. 2019 May 29;14:3983-3993. doi: 10.2147/IJN.S198194. eCollection 2019.
8
New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.用于治疗耐多药和广泛耐药结核病的新型及重新利用的药物。
J Bras Pneumol. 2018 Apr;44(2):153-160. doi: 10.1590/s1806-37562017000000436.
9
Multimetallic Microparticles Increase the Potency of Rifampicin against Intracellular Mycobacterium tuberculosis.多金属微颗粒增强利福平对细胞内结核分枝杆菌的效力。
ACS Nano. 2018 Jun 26;12(6):5228-5240. doi: 10.1021/acsnano.7b08264. Epub 2018 May 22.
10
Plumbago auriculata leaf extract-mediated AgNPs and its activities as antioxidant, anti-TB and dye degrading agents.蓝花丹叶提取物介导的银纳米粒子及其作为抗氧化剂、抗结核剂和染料降解剂的活性。
J Biomater Sci Polym Ed. 2017 Nov;28(16):1847-1858. doi: 10.1080/09205063.2017.1354673. Epub 2017 Jul 20.